Topics

Boehringer adds to obesity alliance with Denmark’s Gubra

09:11 EDT 30 May 2019 | pharmaphorum

Two years after they started working together, Boehringer Ingelheim and Gubra have taken their obesity collaboration to a higher level. Boehringer is pledging €240 million in upfront and development and commercial milestones to the Danish biotech ...

Original Article: Boehringer adds to obesity alliance with Denmark’s Gubra

NEXT ARTICLE

More From BioPortfolio on "Boehringer adds to obesity alliance with Denmark’s Gubra"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Endocrinology
Diabetes Diabetes Endocrine Disorders Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several g...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...